Predict your next investment

Elucida Oncology company logo
HEALTHCARE | Biotechnology
elucidaoncology.com

See what CB Insights has to offer

Founded Year

2014

Stage

Series A - III | Alive

Total Raised

$72.54M

Last Raised

$35M | 1 yr ago

About Elucida Oncology

Elucida Oncology is focused on transforming outcomes for patients with primary solid tumors and metastatic cancer. The company leverages the Target or Clear capabilities of its ultra-small C-Dot cancer-targeting particle platform across diagnostic imaging, surgical and a wide range of therapeutic applications.

Elucida Oncology Headquarter Location

1 Deer Park Drive Suite E

Monmouth Junction, New Jersey, 08852,

United States

Latest Elucida Oncology News

Elucida Oncology Appoints Ian Somaiya as Chief Financial Officer and Chief Business Officer

Nov 22, 2021

Monmouth Junction, New Jersey, UNITED STATES MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today the appointment of Ian Somaiya as Chief Financial Officer and Chief Business Officer. Mr. Somaiya brings to Elucida more than 20 years of experience in finance and healthcare as a highly regarded biotechnology research analyst as well as operational experience as Chief Financial Officer of TCR2 Therapeutics. “We are thrilled to welcome Ian to our team. As the company enters its next stage of growth and development, his exceptional financial and banking experience, deep relationships within the investment community, and overall business acumen will be a compliment to the talented executive team we have already attracted at Elucida Oncology,” stated Geno Germano, CEO and President of Elucida Oncology. “I am extremely impressed with the progress the team has made bringing its first-in-class, potentially game-changing C’Dot-drug-conjugate platform into the clinic,” said Mr. Somaiya. “It is exciting to join Elucida at such a critical time, with clinical data for its lead program targeting folate-receptor alpha (FRα) in 2022 representing a key inflection point for the company and its shareholders. I look forward to working with the seasoned management team and Board to bring new effective and safe precision medicines to cancer patients in need,” concluded Mr. Somaiya. Mr. Somaiya has over two decades of experience in finance and biotechnology. Most recently, he was Chief Financial Officer of TCR2 Therapeutics where he successfully navigated the company through its IPO and two follow-on financings. During his nearly four years at TCR2, he led the company’s finance and public company reporting as well as business development and investor relations functions. Prior to joining TCR2, Mr. Somaiya spent over 20 years on Wall Street where he conducted extensive research on more than 100 biotechnology companies across diverse therapeutic areas, technology platforms and stages of development. He was Managing Director and Head of Biotechnology Research at BMO Capital Markets, and also served as a Managing Director and Equity Analyst at Nomura Securities Co. Ltd., Piper Jaffray Companies and Thomas Weisel Partners Group, Inc. He launched his Wall Street career as a research analyst at Morgan Stanley and Prudential Securities and was recognized as the "Best on the Street" by The Wall Street Journal for his coverage on biotechnology in 2006, 2007 and 2009. Mr. Somaiya received a Bachelor of Arts degree in Biology and Neuroscience from New York University. About Elucida Oncology Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle C’Dot drug delivery platform. The company’s C’Dot-Drug-Conjugates, or CDCs, are novel drug candidates with unique Target or Clear® properties designed to substantially increase delivery of highly potent drugs to difficult to treat tumors with minimal systemic exposure due to their rapid clearance in the kidneys. CDCs enable precise tumor targeting and deep tumor penetration as demonstrated in preclinical studies, resulting in enhanced efficacy with reduced off-target toxicity, thereby potentially addressing the limitations of antibody-drug-conjugates (ADCs) and more traditional drug carriers. For more information on Elucida Oncology, Inc., please visit www.elucidaoncology.com . Contact Info:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Elucida Oncology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Elucida Oncology is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

M

Medical Devices

7,884 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Elucida Oncology Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Elucida Oncology Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.